References

  1. Gupta A, Montepiedra G, Aaron L, Theron G, McCarthy K, Bradford S et al. Isoniazid Preventive therapy in HIV-infected pregnant and postpartum women. N Engl J Med. 2019;381(14):1333–46. doi:10.1056/NEJMoa1813060
  2. Montepiedra G, Aaron L, Theron G, McCarthy K, Bradford S, Chipato T et al. Hepatotoxicity among people living with HIV and receiving isoniazid preventive therapy in pregnancy and postpartum: The role of antiretroviral regimen and pharmacogenetics. Clin Infect Dis. 2025. doi:10.1093/cid/ciaf198
  3. Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and rifapentine with pharmacokinetics of dolutegravir (DTG) in pregnant people With HIV (DOLPHIN Moms) [website]. (https://clinicaltrials.gov/study/NCT05122026, accessed 22 February 2026).
  4. Kurbatova EV, Whitworth WC, Bryant KE, Dixon MG, Dooley KE, Scott NA et al. Pregnancy outcomes after exposure to tuberculosis treatment in phase 3 clinical trial, 2016–2020. Emerg Infect Dis. 2025;31(12):2233–42. doi:10.3201/eid3112.250492
  5. Moro RN, Scott NA, Vernon A, Tepper NK, Goldberg SV, Schwartzman K et al. Exposure to latent tuberculosis treatment during pregnancy. The PREVENT TB and the iAdhere Trials. Ann Am Thorac Soc. 2018;15(5):570–80. doi:10.1513/AnnalsATS.201704-326OC
  6. de Oliveira MCB, Sant'Anna CC, Raggio Luiz R, Kritski AL. Unfavorable outcomes in tuberculosis: Multidimensional factors among adolescents in Rio de Janeiro, Brazil. Am J Trop Med Hyg. 2020;103(6):2492–500. doi:10.4269/ajtmh.20-0209
  7. Enane LA, Lowenthal ED, Arscott-Mills T, Matlhare M, Smallcomb LS, Kgwaadira B et al. Loss to follow-up among adolescents with tuberculosis in Gaborone, Botswana. Int J Tuberc Lung Dis. 2016;20(10):1320–5. doi:10.5588/ijtld.16.0060
  8. Mulongeni P, Hermans S, Caldwell J, Bekker L-G, Wood R, Kaplan R. HIV prevalence and determinants of loss-to-follow-up in adolescents and young adults with tuberculosis in Cape Town. PLOS ONE. 2019;14(2):e0210937. doi:10.1371/journal.pone.0210937
  9. Reif LK, Rivera V, Bertrand R, Rouzier V, Kutscher E, Walsh K et al. Outcomes across the tuberculosis care continuum among adolescents in Haiti. Public Health Action. 2018;8(3):103–9. doi:10.5588/pha.18.0021
  10. Ginsberg G, Hattis D, Sonawane B, Russ A, Banati P, Kozlak M et al. Evaluation of child/adult pharmacokinetic differences from a database derived from the therapeutic drug literature. Toxicol Sci. 2002;66(2):185–200. doi:10.1093/toxsci/66.2.185
  11. Fernandez E, Perez R, Hernandez A, Tejada P, Arteta M, Ramos JT. Factors and mechanisms for pharmacokinetic differences between pediatric population and adults. Pharmaceutics. 2011;3(1):53–72. doi:10.3390/pharmaceutics3010053
  12. S. LaCourse, J. Mathad, L. Varughese, B.A.S. Nonyane, S. Kim, J. Moodley et al. Safety of rifapentine-based TB prevention in pregnant women with HIV on dolutegravir: DOLPHIN-Moms trial. [Abstract: 56th Union World Conference on Lung Health. Copenhangen, Denmark; 2025] Int J Tuberc Lung Dis. 2025;29(11):S773 (https://documents.theunion.org/web-uploads/UNION2025_Abstracts_Medium.pdf, accessed 22 February 2026).
  13. Hernán MA, Wang W, Leaf DE. Target Trial Emulation: A framework for causal inference from observational data. JAMA. 2022;328(24):2446–7. doi:10.1001/jama.2022.21383
  14. Eke AC. An update on the physiologic changes during pregnancy and their impact on drug pharmacokinetics and pharmacogenomics. J Basic Clin Physiol Pharmacol. 2022;33(5):581–98. doi:10.1515/jbcpp-2021-0312
  15. WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-resistant tuberculosis treatment, 2022 update. Geneva: World Health Organization; 2022 (https://iris.who.int/handle/10665/365308, accessed 22 February 2026).
  16. Martinez L, Cords O, Horsburgh CR, Andrews JR, Acuna-Villaorduna C, Desai Ahuja S et al. The risk of tuberculosis in children after close exposure: a systematic review and individual-participant meta-analysis. Lancet. 2020;395(10228):973–84. doi:10.1016/s0140-6736(20)30166-5
  17. Loveday M, Hughes J, Sunkari B, Master I, Hlangu S, Reddy T et al. Maternal and infant outcomes among pregnant women treated for multidrug/rifampicin-resistant tuberculosis in South Africa. Clin Infect Dis. 2021;72(7):1158–68. doi:10.1093/cid/ciaa189
  18. Clinical management of rifampicin-resistant tuberculosis: Updated clinical reference guide. Department of Health, Republic of South Africa; 2023 (https://tbthinktank.org/wp-content/uploads/2024/06/RR-TB-Clinical-Guide-Reference-Book-Final.pdf, accessed 22 February 2026).
  19. WHO consolidated guidelines on tuberculosis: module 1: prevention: tuberculosis preventive treatment, second edition. Geneva: World Health Organization; 2024 (https://iris.who.int/handle/10665/378536, accessed 22 February 2026).
  20. Eke AC, Olagunju A, Momper J, Penazzato M, Abrams EJ, Best BM et al. Optimizing pharmacology studies in pregnant and lactating women using lessons from HIV: A consensus statement. Clin Pharmacol Ther. 2021;110(1):36–48. doi:10.1002/cpt.2048
  21. Sawe S, Tsirizani L, Court R, Gausi K, Poswa A, Badat T et al. The effect of pregnancy on the population pharmacokinetics of levofloxacin in South Africans with rifampicin-resistant tuberculosis. Antimicrob Agents Chemother. 2025;69(5):e01626–24. doi:10.1128/aac.01626-24
  22. Court R, Gausi K, Mkhize B, Wiesner L, Waitt C, McIlleron H et al. Bedaquiline exposure in pregnancy and breastfeeding in women with rifampicin-resistant tuberculosis. Br J Clin Pharmacol. 2022;88(8):3548–58. doi:10.1111/bcp.15380
  23. Abdelwahab MT, Wasserman S, Brust JCM, Gandhi NR, Meintjes G, Everitt D et al. Clofazimine pharmacokinetics in patients with TB: dosing implications. J Antimicrob Chemother 2020;75(11):3269–77. doi:10.1093/jac/dkaa310
  24. Hughes JA, McMorrow F, Brooks KM, Pinilla M, Fairlie L, Ngocho JS et al. Pharmacokinetics and safety of clofazimine in women with rifampicin-resistant tuberculosis during pregnancy and the postpartum period: Results from IMPAACT P1026s. J Infect Dis. 2025;233(1):16–26. doi:10.1093/infdis/jiaf504
  25. Sawe S, Tsirizani L, Mkhize B, Wiesner L, Maartens G, Conradie F et al. Population pharmacokinetics of levofloxacin in breastmilk in patients with rifampicin-resistant tuberculosis. Br J ClinPharmacol. doi:10.1002/bcp.70386
  26. Ueckert S, Karlsson MO, Hooker AC. Accelerating Monte Carlo power studies through parametric power estimation. J Pharmacokinet Pharmacodyn. 2016;43(2):223–34. doi:10.1007/s10928-016-9468-y
  27. Prendergast AJ, Goga AE, Waitt C, Gessain A, Taylor GP, Rollins N et al. Transmission of CMV, HTLV-1, and HIV through breastmilk. Lancet Child Adolesc Health. 2019;3(4):264–73. doi:10.1016/S2352-4642(19)30024-0
  28. Gasparyan J, Anderson PO, Lewis T, Yeung CHT. Rules of thumb for estimating drug levels in breast milk: How well do they work? Clin Pharmacol Ther. 2026;119(1):101–8. doi:1002/cpt.70021
  29. Pansari A, Pan X, Almond LM, Rowland-Yeo K. A tutorial on physiologically based pharmacokinetic approaches in lactation research. CPT Pharmacometrics Syst Pharmacol. 2024;13(11):1841–55. doi:10.1002/psp4.13232
  30. Wood ND, Smith D, Kinrade SA, Sullivan MT, Rayner CR, Wesche D et al. The use of quantitative clinical pharmacology approaches to support moxidectin dosing recommendations in lactation. PLoS Negl Trop Dis. 2024;18(8):e0012351. doi:10.1371/journal.pntd.0012351
  31. Humphries H, Almond L, Berg A, Gardner I, Hatley O, Pan X et al. Development of physiologically-based pharmacokinetic models for standard of care and newer tuberculosis drugs. CPT Pharmacometrics Syst Pharmacol. 2021;10(11):1382–95. doi:10.1002/psp4.12707
  32. Johnson TN, Batchelor HK, Goelen J, Horniblow RD, Dinh J. Combining data on the bioavailability of midazolam and physiologically-based pharmacokinetic modeling to investigate intestinal CYP3A4 ontogeny. CPT Pharmacometrics Syst Pharmacol. 2024;13(9):1570–81. doi:10.1002/psp4.13192
  33. Karakitsios E, Della Pasqua O, Dokoumetzidis A. Extrapolation of lung pharmacokinetics of bedaquiline across species using physiologically-based pharmacokinetic modelling. Br Clin Pharmacol. 2025;91(11):3167–78. doi:0.1002/bcp.70163
  34. Otieno D, Ojara FW, Richardson N, Waitt C, Zhao P, Hartman D. Treating pregnant and lactating women: Insights from clinical pharmacology. Annu Rev Pharmacol Toxicol. 2026;66(1):191–210. doi:10.1146/annurev-pharmtox-071724-014725
  35. Mkhize B, Kellermann T, Norman J, Castel S, Joubert A, van der Merwe M et al. Validation and application of a quantitative liquid chromatography tandem mass spectrometry assay for the analysis of rifapentine and 25-O-desacetyl rifapentine in human milk. J Pharm Biomed Anal. 2022;215:114774. doi:10.1016/j.jpba.2022.114774
  36. Consolidated guidance on tuberculosis data generation and use: module 1: tuberculosis surveillance. Geneva: World Health Organization; 2024 (https://iris.who.int/handle/10665/376612, accessed 22 February 2026).
  37. Hamada Y, Figueroa C, Martín-Sánchez M, Falzon D, Kanchar A. The safety of isoniazid tuberculosis preventive treatment in pregnant and postpartum women: systematic review and meta-analysis. Eur Respir J. 2020;55(3):1901967. doi:10.1183/13993003.01967-2019
  38. Theron G, Montepiedra G, Aaron L, McCarthy K, Chakhtoura N, Jean-Philippe P et al. Individual and composite adverse pregnancy outcomes in a randomized trial on isoniazid preventative therapy among women living with human immunodeficiency virus. Clin Infect Dis. 2020;72(11):e784–e90 doi:10.1093/cid/ciaa1482
  39. G. Montepiedra, P. Singh, L. Aaron, R. Becquet, R. Chaisson, S. Swindells et al. Adverse pregnancy outcomes and isoniazid exposure during pregnancy: Systematic review and individual participant data meta-analysis of women living with HIV. [Abstract: 53rd Union World Conference on Lung Health. Paris, France; 2023]. Int J Tuberc Lung Dis. 2023;27(S1):S273. (https://conf2023.theunion.org/wp-content/uploads/2023/12/UNION2023_Abstracts.pdf, accessed 22 February 2026).
  40. Optimal and early inclusion of pregnant and lactating women in tuberculosis research: consensus statement. Geneva: World Health Organization; 2025 (https://iris.who.int/handle/10665/381875).